YouTube & Expert Fact Checks

A transparent 6-month grey-market diary that largely aligns with clinical data, including DEXA-confirmed muscle loss and a plausible PPI interaction warning.

Andrew Huberman

Stanford neuroscientist · Podcast

Mostly accurate

Most of Huberman’s claims are accurate or well-supported, though he overstated the speed of weight loss and his guest’s "fewer side effects" claim is unsupported.

Nap's reporting is largely accurate and well-sourced, and he responsibly warns that cross-trial comparisons of UBT-251 and retatrutide are unreliable.

Very accurate overall — his mechanism, Phase 2 data, comparisons, and side-effect numbers match published sources, with only the dysesthesia signal omitted.

Dr. Amin Hedayat

Triple board-certified pathologist · YouTube

Mostly accurate

One of the more accurate and well-sourced YouTube analyses; the main overstatement is the heart-rate figure, with anhedonia framed as plausible but unconfirmed.

Dr. Ashley Froese

Physician · YouTube

Mostly accurate

Dr. Froese's explanations are generally well-supported by published data, with only minor inaccuracies like conflating lean mass with muscle and misstating dose arms.

Dr. Dan's presentation of the Phase 2 data is largely accurate and well-balanced, with only the underweight-BMI claim overstated.

One of the more accurate physician-led overviews; the main errors are misattributing the 24-week maximum to the 8mg dose and a fewer-side-effects prediction Phase 3 disproved.

His top-line potency claim holds, but he garbles the receptor mechanism, wrongly denies side effects, overstates muscle preservation, and sells the product he reviews.

His reconstitution and injection technique is broadly sound, but his sub-clinical dosing and grey-market product lack any supporting clinical evidence.

Jones gets most headline trial numbers right, but his heart-rate claim is significantly overstated, his Phase 2 threshold breakdown has errors, and his food-chatter framework is anecdotal.

Miller's mechanism claims are largely supported, but he badly understates the weight loss, overstates muscle preservation, and promotes unstudied grey-market peptide stacks.

Morelli's triple agonist mechanism is broadly correct, but he significantly overstates muscle-building and cognitive claims and misleadingly promotes grey-market peptides and non-standard dosing.

Mostly accurate on the TRIUMPH-4 headline data, but his 80% dropout claim is substantially wrong and his unsupervised grey-market peptide stack is entirely anecdotal.

JD Denham

Peptide of the Week host · YouTube

Mostly wrong

The triple-agonist framework is correct, but the no-nausea claim and every dosing recommendation diverge dangerously from clinical trial data.

The fabricated 3x/week, 333mcg, 10-12 week cycle protocol contradicts every clinical trial and pairs with commercially motivated branded-supplement promotion.